Dendritic cell

PDC*line Pharma Completes Enrolment of Four Cohorts of Patients in PDC-LUNG-101 Phase I/II Clinical Trial

Retrieved on: 
Wednesday, December 6, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Data, Safety, NY-ESO-1, Non-small-cell lung cancer, Clinical trial, ESMO, Patient, DSMB, Pembrolizumab, MUC1, PD-1, MAGE, Dendritic cell, Cancer, PDC, KU Leuven, Mutation, Pharmaceutical industry, Vaccine, NSCLC

The objectives of the phase I/II trial (PDC-LUNG-101) were to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.

Key Points: 
  • The objectives of the phase I/II trial (PDC-LUNG-101) were to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.
  • The trial was conducted at 17 clinical sites in France, Belgium, Germany, the Netherlands and Poland.
  • “We are pleased to have achieved full patient enrolment in the PDC-LUNG-101 clinical trial, a key step in the product’s clinical development and another important milestone for PDC*line Pharma.
  • “I would like to extend my gratitude to the investigators and patients across the five countries included in our clinical trial.

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Society for Immunotherapy of Cancer, Human, Dendritic cell, UNO, Mouse, SITC, Immunotherapy, B cell, Immune system, Annual general meeting, Dendrite, Safety, Society, Patient, Toxicity, Rare-earth element, Vaccine, Pharmaceutical industry, Cancer

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced encouraging first-in-human and first-in-class clinical data demonstrating a promising safety profile and clear evidence of immune system activation via biomarker response. The single agent treatment in relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous malignancies represents an unprecedented use of ultra-high concentration nitric oxide as an immunotherapeutic. These data were presented today at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, which is being held in San Diego, California from November 1st to 5th via a poster presentation of abstract number 733.

Key Points: 
  • The single agent treatment in relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous malignancies represents an unprecedented use of ultra-high concentration nitric oxide as an immunotherapeutic.
  • These data were presented today at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, which is being held in San Diego, California from November 1st to 5th via a poster presentation of abstract number 733.
  • “The development of immunotherapy has pushed the frontier of cancer medicine further than ever expected,” stated Dr. Jedidiah Monson, Chief Medical Officer.
  • In addition, more than a 150% increase in T-central memory cells was observed, consistent with previously reported murine data (Sela Y et al.

New RNA-based Therapy Combats Melanoma in Mouse Models; Experimental approach that triggers a type of immune cell may be beneficial against cancers in humans

Retrieved on: 
Thursday, July 27, 2023
Ohio State University, B-cell lymphoma, Icahn School of Medicine at Mount Sinai, Neoplasm, Genomics, COVID-19, State university system, Cancer, National Institute of General Medical Sciences, Icahn Genomics Institute, Mount Sinai, Cell, RNA, Doctor of Philosophy, Associate, National Cancer Institute, Dendritic cell, Patient, Melanoma, DOI, Marc, Mouse, Nature Nanotechnology, Recurrence, B cell, Breast cancer, Vaccine, Pharmaceutical industry

NEW YORK, July 27, 2023 /PRNewswire-PRWeb/ -- Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.

Key Points: 
  • Cancer cells employ strategies to switch off various stages of the cancer-immunity cycle, the process by which dendritic cells educate T cells to kill cancer cells.
  • Their investigations revealed encouraging results, as the regimen reduced tumors in mouse models of B cell lymphoma by 83 percent.
  • They also tested it in mouse models of breast cancer, where approximately half of the mice favorably responded.
  • The study was funded in part by National Cancer Institute grant P30 CA016058 and National Institute of General Medical Sciences grant R35GM144117.

Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors

Retrieved on: 
Thursday, April 27, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Doctor, CRC, T cell, Pharming, Safety, DC, CAM, Cancer, Toxicity, Doctor of Philosophy, STC, TCR, Dendritic cell, Patient, Stimulated, Colorectal cancer, Master of Science, Immune system, Cross-presentation, Neoplasm, Team, Pharmaceutical industry, Vaccine, Antibiotics, Management

Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform.

Key Points: 
  • Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform.
  • These models comply with the FDA’s modernization act 2.0 S. 5002 and demonstrate the potential of STC-1010 in clinical settings for the treatment of patients with colorectal cancer.
  • The first study evaluated the safety and efficacy of STC-1010 in activating the antitumoral immune response against human colorectal adenocarcinoma using the chicken CAM assay.
  • Results obtained in-ovo confirmed the anti-tumor efficacy -mediated by cytokine secretion and T cells expansion- of the vaccine previously observed in CRC syngeneic mouse models.

Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio

Retrieved on: 
Friday, January 20, 2023
B cell, Nanoparticle, Immunotherapy, Gene silencing, Survivin, DNA, Dendritic cell, Immunity, Cell, OTC, Dendrite, RNA, Exosome, SAN, Breast cancer, Science, Immune system, Vaccine

SAN DIEGO, Jan. 20, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs announced today the filing of a provisional patent application covering the use of survivin-engineered dendritic cells and exosomes for stimulation of anti-cancer immunity.  The intellectual property provides additional means of stimulating specific elements of the immune system to selectively seek and destroy cancer cells without harming healthy tissue. 

Key Points: 
  • The intellectual property provides additional means of stimulating specific elements of the immune system to selectively seek and destroy cancer cells without harming healthy tissue.
  • Dendritic cells are the most potent immune cell capable of activating T cells.
  • The cancer marker survivin appears to be present on most of the major cancers but not on non-malignant tissues.
  • The Company has previously designed dendritic cells for treatment of breast cancer utlizing a process called gene silencing.

PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022

Retrieved on: 
Friday, December 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Memory, Peptide, Melanoma, Blood bank, PBMC, HLA-A2, B cell, Antigen, Large-cell lung carcinoma, NK, Poster, MUC1, Patient, NY-ESO-1, PDC, Lung cancer, Hlas, GMP, Non-small-cell lung carcinoma, PD-1, RECIST, White blood cell, Safety, Cancer, Dendritic cell, ESMO, Human, RNA transfection, LOQ, Clinical trial, Growth, Bioreactor, MAGE, EFS, Pembrolizumab, Mutation, Pharmaceutical industry, Vaccine, NSCLC

The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).

Key Points: 
  • The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).
  • The objectives of the phase I/II trial (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.
  • It is administered weekly by a subcutaneous and intravenous route, in six consecutive doses.
  • Safety and clinical activity of the product were presented at ESMO 2022 in September 2022 in Paris (France).

PDC*line Pharma Presents First Clinical Results From Phase I/II trial With PDC*lung01 at ESMO 2022

Retrieved on: 
Tuesday, September 13, 2022
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Science, Oncology, MUC1, Safety, Memory, Blood bank, RNA transfection, Bioreactor, Hlas, Hope, Data monitoring committee, KU Leuven, Population, European Society for Medical Oncology, Growth, Progression-free survival, NY-ESO-1, Melanoma, MAGE, Lung cancer, Patient, Degenerative disease, RECIST, CEO, Dendritic cell, Technology, Oncology, DLT, Large-cell lung carcinoma, SAE, PDC, EFS, PD-L1, PD-1, Mutation, Cancer, PBMC, GMP, B cell, Non-small-cell lung carcinoma, ESMO, Pharmaceutical industry, Vaccine, A2, NSCLC, A1

The preliminary data was presented today at a poster discussion session at the 2022 European Society for Medical Oncology (ESMO) Annual Meeting.

Key Points: 
  • The preliminary data was presented today at a poster discussion session at the 2022 European Society for Medical Oncology (ESMO) Annual Meeting.
  • The objectives of the phase I/II trial (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated with, or not, anti-PD-1 treatment in NSCLC patients.
  • Results are reported on the first three cohorts that have been completed (A1/A2/B1).
  • With preliminary clinical data now available from patients of the first three enrolled cohorts, it is encouraging to see PDC*lung01 as safe, immunogenic and to have signs of clinical efficacy.

DGAP-News: DEFENCE THERAPEUTICS: AN ANTI-CANCER SOLUTIONS PLATFORM COMPANY ADVANCING ITS VERSATILE ACCUM TECHNOLOGY

Retrieved on: 
Friday, April 1, 2022
Company, Cancer, PDX, Therapy, Cell, University, E6, Ministry of Education (Malaysia), Forward-looking statement, Fortis Healthcare, ADC, ATF, GLP, News, Vaccine, DGAP, Research, Accum, Program, University of Birmingham, E7, EU, Documentation, Control, Dendritic cell, Technology, MHRA, Cervical cancer, Melanoma, Infection, Catastrophic illness, Animal, Curie Institute, Curie Institute (Paris), Breast cancer, Engineering, Health Canada, CSE, Security (finance), Dietary supplement, Pharmaceutical industry, BC, Defense

Defence is also advancing, at a fast pace, its ADC program against breast cancer.

Key Points: 
  • Defence is also advancing, at a fast pace, its ADC program against breast cancer.
  • Defence's lead ADC will be then tested under GLP standards prior to initiate a Phase I Trial against breast cancer.
  • "Defence Therapeutics is well position to prevent cancer with his versatile technology: a solution looking for a cancer to prevent and to treat.
  • The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.

Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board

Retrieved on: 
Monday, September 20, 2021
Technology, Research, Infectious Diseases, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Therapy, VU University Medical Center, JAK3, List of pathologists, KNAW, Dendrite, ERC, Cell, Royal Netherlands Academy of Arts and Sciences, Harvard Medical School, SCID, Aviceda, Inflammation, Pathology, Coronavirus Scientific Advisory Board (Turkey), Cell biology, IP, Immune system, Cancer research, Science, Amgen, JEM, HIV, COO, GA, UCLA, FIH, CSO, Molecular biology, Ghost, DNA repair, DNA, Geographic atrophy, Government, Autosome, Cancer Research UK, Doctor of Philosophy, College, Government of Northern Ireland, Society, Dendritic cell, College of American Pathologists, DNAR, II, NWO, Cancer, CLIA, Patient, Biomarker, Biology, CLEP, McClay, NIH, PNAS, Pharmaceutical industry, Vaccine, Medicine

Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.

Key Points: 
  • Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.
  • The new additional Aviceda Scientific Advisory Board members includes:
    Aviceda is honored and privileged to add new world-class scientists and renowned researchers to join our efforts in developing the next generation of glyco-immune therapeutics for the treatment of immune-dysfunction conditions, said Mohamed A. Genead, MD, Co-Founder & President of Aviceda Therapeutics.
  • She published more than 280 scientific papers in well recognized journals (Cell, Nature, Nature Immunology, PNAS, and JEM) and supervised 29 PhD students.
  • The Aviceda team is already building on the foundational work in the emerging field of glycobiology to develop potential therapeutics and interventional strategies.

Therapeutic Solutions International Patents Modified StemVacs Dendritic Cell Immunotherapy to Suppress Parkinson's Disease in Animal Model

Retrieved on: 
Tuesday, July 6, 2021
Branches of biology, Medical specialties, Medicine, Immunology, Medical terminology, Neuron, Inflammation, Immunotherapy, Dendritic cell

ELK CITY, Idaho, July 6, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a new patent and data utilizing "tolerogenic dendritic cells" obtained from umbilical cord blood for suppression of Parkinson's Disease in an animal model.

Key Points: 
  • ELK CITY, Idaho, July 6, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a new patent and data utilizing "tolerogenic dendritic cells" obtained from umbilical cord blood for suppression of Parkinson's Disease in an animal model.
  • The data, which was filed in a patent application, demonstrates that a specifically modified StemVacs dendritic cell is capable at suppressing brain inflammation, as well as preserving dopaminergic neurons in the brain.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
  • 3 Seo, J., et al., Chronic Infiltration of T Lymphocytes into the Brain in a Non-human Primate Model of Parkinson's Disease.